<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01408030</url>
  </required_header>
  <id_info>
    <org_study_id>GHSU 1008041</org_study_id>
    <nct_id>NCT01408030</nct_id>
  </id_info>
  <brief_title>North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)</brief_title>
  <acronym>NOSE</acronym>
  <official_title>North American Study of Epistaxis in HHT (NOSE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>James Gossage</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HHT Foundation International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Augusta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the NOSE Study is to carefully examine the efficacy and safety of 3 nasal
      sprays (bevacizumab, estriol, and tranexamic acid), compared to placebo, for the treatment of
      HHT related nosebleeds.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      140 patients with moderate to severe epistaxis secondary to HHT will be randomized to receive
      one of four intranasal sprays for a period of 12 weeks and then followed for an additional 12
      weeks off therapy. Enrollment will occur over a period of 18-36 months. The primary endpoint
      will be the frequency of epistaxis. Secondary endpoints will include duration of epistaxis,
      the Hoag Epistaxis Severity Score (ESS), a quality of life survey, satisfaction with
      treatment, hemoglobin and ferritin levels, transfusion requirements, and treatment failure.
      The sprays will be: saline spray (Placebo); estriol 0.1% in methylcellulose suspension (EST);
      tranexamic acid 10% in saline (TA), and bevacizumab 1% in saline (BEV). All sprays will be
      applied to the nasal mucosa by an identical spray bottle at a dose of 0.1 ml per nostril
      twice daily (total dose of 0.4 ml daily). Thus, the delivered doses will be: EST, 0.4 mg/day;
      TA, 40 mg/day; BEV, 4 mg/day.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Epistaxis</measure>
    <time_frame>Weeks 5-12 of active treatment phase</time_frame>
    <description>Bleeding episodes per week</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Epistaxis</measure>
    <time_frame>5-12 weeks of active treatment</time_frame>
    <description>Total minutes of bleeding per week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hoag Epistaxis Severity Score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Hoag Epistaxis Severity Score (ESS) is based on 6 nosebleed variables such as frequency and duration which are entered by patients. The ESS has a minimum value of 0 and maximum value of 10, with 10 representing more severe epistaxis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Level</measure>
    <time_frame>12 weeks</time_frame>
    <description>grams/100 ml, assessed at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Requiring Red Blood Cell (RBC) Transfusion</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of participants requiring RBC transfusion during weeks 1-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Failure</measure>
    <time_frame>Baseline through 12 weeks</time_frame>
    <description>Treatment failure is defined as the occurrence of one or more of the following during the study: need for nasal surgery or chemical cautery or other new treatment modality to control epistaxis; transfusion of more than 12 units of RBC; severe complications such as acute myocardial infarction, venous thromboembolism, brain hemorrhage; or death</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Telangiectasia, Hereditary Hemorrhagic</condition>
  <condition>Epistaxis</condition>
  <arm_group>
    <arm_group_label>Placebo spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sterile saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bevacizumab 1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Estriol spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Estriol 0.1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tranexamic acid spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tranexamic acid 10%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sterile saline</intervention_name>
    <description>0.9%, 0.1 ml spray in each nostril bid</description>
    <arm_group_label>Placebo spray</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>1% solution in saline, 0.1 ml spray in each nostril bid</description>
    <arm_group_label>Bevacizumab spray</arm_group_label>
    <other_name>Avastin</other_name>
    <other_name>Vascular endothelial growth factor (VEGF) inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estriol</intervention_name>
    <description>0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid</description>
    <arm_group_label>Estriol spray</arm_group_label>
    <other_name>Estrogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>10% solution in saline, 0.1 ml spray in each nostril bid</description>
    <arm_group_label>Tranexamic acid spray</arm_group_label>
    <other_name>Lysteda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A diagnosis of definite or possible HHT by the Curacao criteria (Shovlin 2000) or a
             positive DNA test for HHT (as characterized by a disease causing mutation in the gene
             coding for endoglin, activin like kinase 1, or SMAD-4). According to the Curacao
             criteria, a definite diagnosis of HHT is defined as having at least 3 of the following
             criteria while a possible diagnosis is defined as 2 criteria:

               1. Spontaneous and recurrent epistaxis.

               2. Multiple telangiectasias at characteristic sites (lips, oral cavity, fingers,
                  nose).

               3. Visceral lesions such as gastrointestinal telangiectasias and arteriovenous
                  malformations (AVM) in lung, brain, spine and liver.

               4. A history of definite HHT in a first degree relative using these same criteria.

          2. Epistaxis of at least 1 minute (on average) and which occurs at least once weekly when
             averaged during the preceding 8 weeks.

          3. Epistaxis severity score (ESS) of at least 3.0.

          4. Age of at least 18 years.

          5. Written and informed consent obtained prior to study entry.

          6. Subject is able and willing to return for outpatient visits.

          7. The epistaxis is considered to be clinically stable during the past 8 weeks in the
             clinical judgment of the investigator (i.e. no major changes in frequency or duration
             of epistaxis or in transfusion requirements).

          8. Negative pregnancy test at enrollment.

        Exclusion Criteria:

          1. Allergy to any of the active treatment agents or their spray additives.

          2. Estimated life expectancy less than 1 year.

          3. A psychiatric or substance abuse problem that is expected to interfere with study
             compliance.

          4. History of deep venous thrombosis (DVT), pulmonary embolism (PE), acute myocardial
             infarction (MI), arterial thromboembolism, or ischemic stroke in the past 6 months.6.
             History of receiving more than 12 units of red blood cells in the past 12 weeks.

        7. Presence of an untreated coagulopathy that is felt to be contributing to the 5. History
        of estrogen receptor positive breast cancer. epistaxis. 8. Presence of active disseminated
        intravascular coagulation. 9. Uncontrolled hypertension (systolic BP &gt;160 and/or diastolic
        BP &gt;100). 10. Presence of untreated brain AVM. 11. Presence of active malignancy in the
        brain, lung, or colon. 12. Presence of symptomatic heart failure. 13. Use of estrogens,
        epsilon aminocaproic acid, tranexamic acid, or thalidomide by any route for more than 1
        week in the past 12 weeks. Any use of a VEGF inhibitor by any route in the past 24 weeks.

        14. Baseline use of the following anticoagulants is not allowed: warfarin or other vitamin
        K antagonists at any dose; unfractionated or low molecular weight heparins at standard
        doses for treatment of venous thromboembolism (VTE); or aspirin at &gt;325 mg/day. Baseline
        use of the following anticoagulants is allowed: heparins at standard doses for VTE
        prophylaxis; clopidogrel; or aspirin at â‰¤325 mg/day.

        15. Addition of new treatments for epistaxis in the past 12 weeks (including laser ablation
        of nasal telangiectasias and over the counter medications).

        16. Presence of another overt cause (e.g. overt gastrointestinal bleeding) that is felt to
        be significantly contributing to anemia.

        17. Lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James R Gossage, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Augusta University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Regents University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hht.org</url>
    <description>HHT Foundation website</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>August 1, 2011</study_first_submitted>
  <study_first_submitted_qc>August 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2011</study_first_posted>
  <results_first_submitted>September 11, 2018</results_first_submitted>
  <results_first_submitted_qc>October 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2018</results_first_posted>
  <last_update_submitted>October 9, 2018</last_update_submitted>
  <last_update_submitted_qc>October 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Augusta University</investigator_affiliation>
    <investigator_full_name>James Gossage</investigator_full_name>
    <investigator_title>Director of Pulmonary Vascular Diseases and HHT</investigator_title>
  </responsible_party>
  <keyword>epistaxis</keyword>
  <keyword>HHT</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>tranexamic acid</keyword>
  <keyword>nosebleed</keyword>
  <keyword>estrogen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epistaxis</mesh_term>
    <mesh_term>Telangiectasis</mesh_term>
    <mesh_term>Telangiectasia, Hereditary Hemorrhagic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from the HHT clinics at 6 sites if they met all of the following criteria: age &gt;=18; diagnosis of definite or possible HHT; epistaxis lasting at least 1 minute, occurring at least once weekly, and clinically stable during the preceding 8weeks; and had an Epistaxis Severity Score (ESS) of at least 3.0.</recruitment_details>
      <pre_assignment_details>123 patients provided consent but 1 withdrew consent and 1 was excluded due to brain arteriovenous malformation. Therefore 121 patients were randomized and included in participant flow. 1 patient in the estriol group was subsequently removed after it was discovered that she was taking estrogen outside the protocol (protocol violation).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Bevacizumab Spray</title>
          <description>Bevacizumab: 1% solution in saline, 0.1 ml spray in each nostril bid</description>
        </group>
        <group group_id="P2">
          <title>Estriol Spray</title>
          <description>Estriol: 0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid</description>
        </group>
        <group group_id="P3">
          <title>Tranexamic Acid Spray</title>
          <description>Tranexamic Acid: 10% solution in saline, 0.1 ml spray in each nostril bid</description>
        </group>
        <group group_id="P4">
          <title>Placebo Spray</title>
          <description>Sterile saline: 0.9%, 0.1 ml spray in each nostril bid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Phase (on Drug)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Observation Phase (Off Drug)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bevacizumab Spray</title>
          <description>Bevacizumab: 1% solution in saline, 0.1 ml spray in each nostril bid</description>
        </group>
        <group group_id="B2">
          <title>Estriol Spray</title>
          <description>Estriol: 0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid</description>
        </group>
        <group group_id="B3">
          <title>Tranexamic Acid Spray</title>
          <description>Tranexamic Acid: 10% solution in saline, 0.1 ml spray in each nostril bid</description>
        </group>
        <group group_id="B4">
          <title>Placebo Spray</title>
          <description>Sterile saline: 0.9%, 0.1 ml spray in each nostril bid</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="33"/>
            <count group_id="B4" value="28"/>
            <count group_id="B5" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.8" lower_limit="42.8" upper_limit="52.9"/>
                    <measurement group_id="B2" value="56.6" lower_limit="52" upper_limit="61.2"/>
                    <measurement group_id="B3" value="53" lower_limit="48.2" upper_limit="57.8"/>
                    <measurement group_id="B4" value="53" lower_limit="48.6" upper_limit="57.3"/>
                    <measurement group_id="B5" value="52.8" lower_limit="39.9" upper_limit="65.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Definite HHT</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Epistaxis history</title>
          <units>bleeding episodes per week</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.0" lower_limit="5.0" upper_limit="14.0"/>
                    <measurement group_id="B2" value="7.0" lower_limit="7.0" upper_limit="14.0"/>
                    <measurement group_id="B3" value="7.8" lower_limit="5.5" upper_limit="14.5"/>
                    <measurement group_id="B4" value="7.0" lower_limit="5.0" upper_limit="15.0"/>
                    <measurement group_id="B5" value="7.0" lower_limit="3.0" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Epistaxis severity score</title>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.16" lower_limit="4.75" upper_limit="5.57"/>
                    <measurement group_id="B2" value="5.19" lower_limit="4.71" upper_limit="5.68"/>
                    <measurement group_id="B3" value="5.43" lower_limit="4.94" upper_limit="5.91"/>
                    <measurement group_id="B4" value="5.71" lower_limit="5.04" upper_limit="6.38"/>
                    <measurement group_id="B5" value="5.37" lower_limit="4.71" upper_limit="6.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Epistaxis</title>
        <description>Bleeding episodes per week</description>
        <time_frame>Weeks 5-12 of active treatment phase</time_frame>
        <population>Participants were included in this analysis (106) if they had at least 3 weeks of data during weeks 5-12; therefore the number of participants analyzed do not equal the number who finished the active treatment phase (120). 2 patients were lost to follow up, 5 dropped out before week 5, 6 filled out diaries incorrectly, and 1 had no diary.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab Spray</title>
            <description>Bevacizumab: 1% solution in saline, 0.1 ml spray in each nostril bid</description>
          </group>
          <group group_id="O2">
            <title>Estriol Spray</title>
            <description>Estriol: 0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid</description>
          </group>
          <group group_id="O3">
            <title>Tranexamic Acid Spray</title>
            <description>Tranexamic Acid: 10% solution in saline, 0.1 ml spray in each nostril bid</description>
          </group>
          <group group_id="O4">
            <title>Placebo Spray</title>
            <description>Sterile saline: 0.9%, 0.1 ml spray in each nostril bid</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Epistaxis</title>
          <description>Bleeding episodes per week</description>
          <population>Participants were included in this analysis (106) if they had at least 3 weeks of data during weeks 5-12; therefore the number of participants analyzed do not equal the number who finished the active treatment phase (120). 2 patients were lost to follow up, 5 dropped out before week 5, 6 filled out diaries incorrectly, and 1 had no diary.</population>
          <units>Bleeding episodes per week</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="4.5" upper_limit="10.5"/>
                    <measurement group_id="O2" value="8.0" lower_limit="4.0" upper_limit="12.0"/>
                    <measurement group_id="O3" value="7.5" lower_limit="3.0" upper_limit="11.0"/>
                    <measurement group_id="O4" value="8.0" lower_limit="3.0" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two sided testing was performed with a significance level of 0.05.</non_inferiority_desc>
            <p_value>0.97</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Epistaxis</title>
        <description>Total minutes of bleeding per week</description>
        <time_frame>5-12 weeks of active treatment</time_frame>
        <population>Participants were included in this analysis (112) if they had at least 3 weeks of data during weeks 5-12; therefore the number of participants analyzed do not equal the number who finished the active treatment phase (120). 2 patients were lost to follow up, 5 dropped out before week 5, and 1 had no epistaxis diary.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab Spray</title>
            <description>Bevacizumab: 1% solution in saline, 0.1 ml spray in each nostril bid</description>
          </group>
          <group group_id="O2">
            <title>Estriol Spray</title>
            <description>Estriol: 0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid</description>
          </group>
          <group group_id="O3">
            <title>Tranexamic Acid Spray</title>
            <description>Tranexamic Acid: 10% solution in saline, 0.1 ml spray in each nostril bid</description>
          </group>
          <group group_id="O4">
            <title>Placebo Spray</title>
            <description>Sterile saline: 0.9%, 0.1 ml spray in each nostril bid</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Epistaxis</title>
          <description>Total minutes of bleeding per week</description>
          <population>Participants were included in this analysis (112) if they had at least 3 weeks of data during weeks 5-12; therefore the number of participants analyzed do not equal the number who finished the active treatment phase (120). 2 patients were lost to follow up, 5 dropped out before week 5, and 1 had no epistaxis diary.</population>
          <units>Total minutes of bleeding per week</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5" lower_limit="13" upper_limit="40"/>
                    <measurement group_id="O2" value="36.5" lower_limit="7" upper_limit="70"/>
                    <measurement group_id="O3" value="44.5" lower_limit="13.5" upper_limit="87.5"/>
                    <measurement group_id="O4" value="46" lower_limit="10" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two sided testing was performed with a significance level of 0.05.</non_inferiority_desc>
            <p_value>.47</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hoag Epistaxis Severity Score</title>
        <description>Hoag Epistaxis Severity Score (ESS) is based on 6 nosebleed variables such as frequency and duration which are entered by patients. The ESS has a minimum value of 0 and maximum value of 10, with 10 representing more severe epistaxis.</description>
        <time_frame>12 weeks</time_frame>
        <population>Participants were included in this analysis if they completed week 12 (phase 1) and filled out an ESS score. 1 participant each from the bevacizumab and placebo group did not fill out an ESS score at week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab Spray</title>
            <description>Bevacizumab: 1% solution in saline, 0.1 ml spray in each nostril bid</description>
          </group>
          <group group_id="O2">
            <title>Estriol Spray</title>
            <description>Estriol: 0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid</description>
          </group>
          <group group_id="O3">
            <title>Tranexamic Acid Spray</title>
            <description>Tranexamic Acid: 10% solution in saline, 0.1 ml spray in each nostril bid</description>
          </group>
          <group group_id="O4">
            <title>Placebo Spray</title>
            <description>Sterile saline: 0.9%, 0.1 ml spray in each nostril bid</description>
          </group>
        </group_list>
        <measure>
          <title>Hoag Epistaxis Severity Score</title>
          <description>Hoag Epistaxis Severity Score (ESS) is based on 6 nosebleed variables such as frequency and duration which are entered by patients. The ESS has a minimum value of 0 and maximum value of 10, with 10 representing more severe epistaxis.</description>
          <population>Participants were included in this analysis if they completed week 12 (phase 1) and filled out an ESS score. 1 participant each from the bevacizumab and placebo group did not fill out an ESS score at week 12.</population>
          <units>units on a scale (0-10)</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.54" lower_limit="3" upper_limit="4.08"/>
                    <measurement group_id="O2" value="3.56" lower_limit="2.81" upper_limit="4.3"/>
                    <measurement group_id="O3" value="4.06" lower_limit="3.5" upper_limit="4.61"/>
                    <measurement group_id="O4" value="3.74" lower_limit="3.17" upper_limit="4.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two sided testing was performed with a significance level of 0.05.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>A mixed-model repeated-measures ANOVA was used to analyze ESS for drug and time (baseline, week 12) effects.
Listed P value is for time effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Clinical site and patient were included in the model as random effects.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin Level</title>
        <description>grams/100 ml, assessed at week 12</description>
        <time_frame>12 weeks</time_frame>
        <population>8 participants who finished the active treatment phase did not have a hemoglobin level measured, and thus only 99 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab Spray</title>
            <description>Bevacizumab: 1% solution in saline, 0.1 ml spray in each nostril bid</description>
          </group>
          <group group_id="O2">
            <title>Estriol Spray</title>
            <description>Estriol: 0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid</description>
          </group>
          <group group_id="O3">
            <title>Tranexamic Acid Spray</title>
            <description>Tranexamic Acid: 10% solution in saline, 0.1 ml spray in each nostril bid</description>
          </group>
          <group group_id="O4">
            <title>Placebo Spray</title>
            <description>Sterile saline: 0.9%, 0.1 ml spray in each nostril bid</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Level</title>
          <description>grams/100 ml, assessed at week 12</description>
          <population>8 participants who finished the active treatment phase did not have a hemoglobin level measured, and thus only 99 were analyzed.</population>
          <units>gram/100 ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="11.7" upper_limit="14.1"/>
                    <measurement group_id="O2" value="13.1" lower_limit="12.3" upper_limit="14.9"/>
                    <measurement group_id="O3" value="11.4" lower_limit="10" upper_limit="13.6"/>
                    <measurement group_id="O4" value="13.8" lower_limit="12.6" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two sided testing was performed with a significance level of 0.05.</non_inferiority_desc>
            <p_value>0.43</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline values and random effect of clinic site.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Requiring Red Blood Cell (RBC) Transfusion</title>
        <description>Number of participants requiring RBC transfusion during weeks 1-12</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab Spray</title>
            <description>Bevacizumab: 1% solution in saline, 0.1 ml spray in each nostril bid</description>
          </group>
          <group group_id="O2">
            <title>Estriol Spray</title>
            <description>Estriol: 0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid</description>
          </group>
          <group group_id="O3">
            <title>Tranexamic Acid Spray</title>
            <description>Tranexamic Acid: 10% solution in saline, 0.1 ml spray in each nostril bid</description>
          </group>
          <group group_id="O4">
            <title>Placebo Spray</title>
            <description>Sterile saline: 0.9%, 0.1 ml spray in each nostril bid</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Requiring Red Blood Cell (RBC) Transfusion</title>
          <description>Number of participants requiring RBC transfusion during weeks 1-12</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two sided testing was performed with a significance level of 0.05.</non_inferiority_desc>
            <p_value>0.42</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Failure</title>
        <description>Treatment failure is defined as the occurrence of one or more of the following during the study: need for nasal surgery or chemical cautery or other new treatment modality to control epistaxis; transfusion of more than 12 units of RBC; severe complications such as acute myocardial infarction, venous thromboembolism, brain hemorrhage; or death</description>
        <time_frame>Baseline through 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab Spray</title>
            <description>Bevacizumab: 1% solution in saline, 0.1 ml spray in each nostril bid</description>
          </group>
          <group group_id="O2">
            <title>Estriol Spray</title>
            <description>Estriol: 0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid</description>
          </group>
          <group group_id="O3">
            <title>Tranexamic Acid Spray</title>
            <description>Tranexamic Acid: 10% solution in saline, 0.1 ml spray in each nostril bid</description>
          </group>
          <group group_id="O4">
            <title>Placebo Spray</title>
            <description>Sterile saline: 0.9%, 0.1 ml spray in each nostril bid</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Failure</title>
          <description>Treatment failure is defined as the occurrence of one or more of the following during the study: need for nasal surgery or chemical cautery or other new treatment modality to control epistaxis; transfusion of more than 12 units of RBC; severe complications such as acute myocardial infarction, venous thromboembolism, brain hemorrhage; or death</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two sided testing was performed with a significance level of 0.05.</non_inferiority_desc>
            <p_value>0.08</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Weeks 1-24</time_frame>
      <desc>Patients were queried at various time points about a specific list of key adverse events and asked for any additional side effects that they may have experienced. Nasal symptoms included rhinorrhea, congestion and sneezing but were not monitored in such a way to allow distinction. Nausea and vomiting were not monitored in such a way to allow distinction and are reported collectively as nausea/vomiting.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bevacizumab Spray</title>
          <description>Bevacizumab: 1% solution in saline, 0.1 ml spray in each nostril bid</description>
        </group>
        <group group_id="E2">
          <title>Estriol Spray</title>
          <description>Estriol: 0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid</description>
        </group>
        <group group_id="E3">
          <title>Tranexamic Acid Spray</title>
          <description>Tranexamic Acid: 10% solution in saline, 0.1 ml spray in each nostril bid</description>
        </group>
        <group group_id="E4">
          <title>Placebo Spray</title>
          <description>Sterile saline: 0.9%, 0.1 ml spray in each nostril bid</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision problem</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="33"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Abdomial pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="33"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="29"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="30"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="33"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal symptoms</sub_title>
                <description>New symptoms such as congestion and rhinorrhea; excludes nosebleeds</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="29"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="30"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="33"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>1. One key limitation is the lack of a baseline epistaxis diary. 2. Drug absorption may have been hampered because of local scab and crust formation causing a barrier to drug penetration. 3. Saline may not be a true placebo due to hydration effects.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>James R. Gossage, MD, Medical Director of Cure HHT</name_or_title>
      <organization>Cure HHT</organization>
      <phone>706-721-6789</phone>
      <email>jgossage@augusta.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

